Arcellx

We are a clinical-stage biotechnology company developing cell therapies for cancer and autoimmune diseases. We engineer cell therapies to be safer, more effective, and more accessible. Our approach uses D-Domain technology, paired with our ddCAR and ARC-SparX platforms.

Our key product candidates include anitocabtagene autoleucel (CART-ddBCMA) and ACLX-001. Anitocabtagene autoleucel is being developed for relapsed or refractory multiple myeloma. ACLX-001 is a controllable cell therapy using the ARC-SparX platform, also targeting multiple myeloma.

Arcellx was founded in December 2014, receiving seed money in April 2015 to develop our D-Domain binding scaffold. We secured Series A funding in late 2016/early 2017, followed by IND approval for anitocabtagene autoleucel and Series B funding in October 2019. The first patient was dosed with anitocabtagene autoleucel in February 2020. In April 2021, we received IND approval for ACLX-001 and completed an initial public offering (IPO) in February 2022, trading on the Nasdaq as “ACLX”. We formed a global strategic collaboration with Kite, a Gilead Company, in January 2023 to co-develop and co-commercialize anitocabtagene autoleucel for multiple myeloma. In May 2024, we announced the design for iMMagine-3, a Phase 3 trial comparing anitocabtagene autoleucel with standard of care for relapsed and/or refractory multiple myeloma.

We have offices in Rockville, MD, and Redwood City, CA.

Our mission is to develop cell therapies that are safer, more effective, and broadly accessible, with the goal of curing cancer. Our values focus on developing new technology with patients at the forefront.

Our core values are:

• Character: We value authenticity and doing what is right, fostering trust and ethical conduct.
• Originality: We believe everyone brings unique value, and we respect diverse perspectives and life experiences, which enriches our culture and contributes to our success.
• Determination: We are determined to achieve our goal of curing cancer, continuously improving and persevering through obstacles.
• Audacity: We encourage challenging the status quo, adopting a growth mindset, dreaming big, and acting with a patient-centric approach.
• Collaboration: We emphasize mutual respect and teamwork, knowing that no job is too small and supporting collective growth to achieve shared success.

We foster a culture where patients come first, focusing on developing new technology for treatment. We strive for a purposeful, empathetic, and collaborative team. We foster an inclusive environment where individuals can bring their authentic selves to work, where we prioritize collective success and support each other’s growth. Our work environment offers impactful projects and opportunities for personal and professional development.

We support our community, including the Multiple Myeloma Research Foundation’s annual 5K run in Washington, DC, and San Francisco, CA.

We are a “Certified Great Place to Work” for 2023-2024 and 2024-2025. The San Francisco Chronicle recognized us as one of The SF Bay Area Top Workplaces 2024, and we ranked #4 on San Francisco Business Times’ “Best Places to Work 2023—Small Companies.” Based on employee feedback, we have also received Comparably Awards for Company Outlook, Workplace Satisfaction, Company Leadership, Company Perks & Benefits, and Work-life Balance.

We offer 100% health insurance premium coverage for employees and their families, including medical, dental, and vision. Employees get unlimited flexible time away (FTA) and a 3% employer contribution to their 401k with auto-enrollment. We provide equity compensation through RSU grants and an Employee Stock Purchase Plan (ESPP) for all employees. We offer six months of full-paid leave for birthing parents, two months of full-paid leave for other parents, and adoption assistance. For mental wellness, months without an official holiday include a company-wide 3-day weekend, which we call “Arcellx Days.” We also provide quarterly or annual bonuses based on company goals and tuition reimbursement. Relocation assistance is available for required roles.